A case of successful contribution of therapeutic drug monitoring of valganciclovir as the prophylaxis against cytomegalovirus infection in a lung transplant recipient

• Main Authors: Yoshiki Katada (Author), Keisuke Umemura (Author), Shunsaku Nakagawa (Author), Yurie Katsube (Author), Masahiro Tsuda (Author), Satona Tanaka (Author), Hiroshi Date (Author), Miki Nagao (Author), Tomohiro Terada (Author)
• Format: Book
• Published: BMC, 2024-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Ganciclovir and its prodrug, valganciclovir, are first-line agents for cytomegalovirus infection prophylaxis after lung transplantation. Although valganciclovir prophylaxis is known to result in severe leukopenia as an adverse effect, dosage adjustment based on therapeutic drug m...